Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Swati Goel, Bassam Mahboub, Abdul Wahid Ansari, Mohamad-Hani Temsah, Adel M. Zakri, Elaref Ratemi, Rifat Hamoudi, Qutayba Hamid, Rabih Halwani. Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity. ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020

Member's Comments

No comment yet.

Related content which might interest you: Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Determination of value the biomarkers of an inflammation at atopic asthma exacerbation caused by respiratory infection Source: Annual Congress 2010 - From rare towards common lung diseases: diagnostic and monitoring challenges Year: 2010 The role of Hs-CRP in evaluating asthma severity and asthma control Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Markers of severity and inflammatory profile during exacerbations of severe asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 ECP in saliva: marker of disease activity in mild to moderate pediatric asthma Source: Eur Respir J 2002; 20: Suppl. 38, 142s Year: 2002 Leptin as a specific marker of risk factors in severe bronchial asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Role of interferon-gamma as a marker of asthma severity and control Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 The role of biomarkers in the management of severe asthma Source: International Congress 2019 – Severe asthma guidelines: update 2019 Year: 2019 Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Endogenous airway acidification in children with chronic asthma: clinical implications Source: Eur Respir J 2003; 22: Suppl. 45, 397s Year: 2003 The role of airways 17ß-estradiol as a biomarker of severity in post-menopausal asthma Source: Virtual Congress 2020 – Respiratory homeostasis and structural changes in disease Year: 2020 Induced sputum in asthma and COPD: meassuring type and inflammation activity Source: Eur Respir J 2003; 22: Suppl. 45, 76s Year: 2003 Expression of the β2-adrenoreceptor and M3-cholinoreceptor genes in patients with different severity of asthma and BHR level Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012 IL-33 mRNA in induced sputum cells from allergic rhinitis and asthma patients: a marker of Th-2 phenotype status? Source: International Congress 2017 – Monitoring asthma control Year: 2017 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020